TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14663457
Drug: Quinidine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (600 mg) with oral morphine (30 mg)
Study: 14663457
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with oral morphine (30 mg)
Study: 14663457
Drug: Quinidine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (600 mg) with intravenous morphine (0.15 mg/kg)
Study: 11180040
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with intravenous morphine (0.15 mg/kg)
Study: 10997950
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (7.7 g/day)
Study: 6691715
Drug: UV-B therapy
Normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UV-B therapy
Study: 6691715
Drug: Extra UV-B
Normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra UV-B treatment to leg lesions
Study: 22364419
Drug: Imatinib 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 300 mg daily
Study: 22364419
Drug: Imatinib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 200 mg daily
Study: 22541039
Drug: Treatment (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (specific treatment not detailed)
Study: 19127033
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa inhibitors (GPI), specifically Abciximab
Study: 19127033
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa inhibitors (GPI), specifically Tirofiban
Study: 9539984
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (IT) for IDDM
Study: 8026248
Drug: Cisapride (30-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (30-60 mg/day for 12.6 ± 2.6 months)
Study: 12826988
Drug: Diphenhydramine 50
Normalized name: diphenhydrAMINE 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 50 mg
Study: 31944371
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual plus group sessions (TAU + GS)
Study: 30346097
Drug: Increased temperature
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased temperature (average of 1.4°C over a growing season) and additional rainwater (10% of the monthly mean added weekly, 40% total)
Study: 27727268
Drug: Topical aerosol
Normalized name: Lidocaine Topical Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aerosol containing chlorfenvinphos 4.8%, dichlorphos 0.75% and gentian violet 0.145%
Study: 22577354
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of glucosamine sulfate and NSAIDs
Study: 16977739
Drug: Rimonabant 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant 20 mg/day
Study: 16709309
Drug: Micronised fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronised fenofibrate 200 mg/day
Study: 18937609
Drug: Rimonabant 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant 20 mg/day plus micronised fenofibrate 200 mg/day
Study: 15953425
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of triamcinolone (4 mg)
Study: 15953425
Drug: Retrobulbar injections
Normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Retrobulbar injections of triamcinolone (40 mg, three times)
Study: 10942856
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg sublingual buprenorphine (BUP)
Study: 8774028
Drug: Caffeine (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (exact dosage not specified)
Study: 30122305
Drug: Semaglutide 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide 0.05 mg
Study: 10721926
Drug: Iron-folic acid
Normalized name: folic acid / iron carbonyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-folic acid (IFA) supplements
Study: 26824731
Drug: Multiple micronutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrients (MMN) supplements
Study: 26824731
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (FA) supplements
Study: 25946854
Drug: 5% solution
Normalized name: Introl 75% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% solution of ascorbic acid, 20 ml/day for 20 days
Study: 25946854
Drug: Cytoflavin, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin, 20 ml (10.0 ml/drip 2 times a day) for 10 days
Study: 25946854
Drug: Cytoflavin, extended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin, extended to 20 days with a dose of 10 ml/day from 11th to 20th day
Study: 22500384
Drug: Lamivudine +
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine + Fuzheng Huayu Capsule (FHC)
Study: 20569451
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment groups (Bazedoxifene and Raloxifene)
Study: 17943542
Drug: dydrogesterone 20
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dydrogesterone 20 mg/day
Study: 17943542
Drug: dydrogesterone 30
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dydrogesterone 30 mg/day
Study: 11773939
Drug: Antihypertensive drug
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drug therapy
Study: 10101626
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of morphine (PCA)
Study: 10101626
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of tramadol (PCA)
Study: 10101626
Drug: Morphine (escape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (escape medication for non-responders)
Study: 10101626
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose
Study: 10101626
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose and pain scores during the first 30 min
Study: 25632745
Drug: Tongfu Jinghua
Normalized name: GINGER 4.5 g in 100 mL TOPICAL LIQUID [Gongfu Head Soup Plant and extract platycypresssolution]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongfu Jinghua Decoction (TJD) combined with conventional Western medical treatment
Study: 25632745
Drug: Conventional Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Western medical treatment alone
Study: 18523036
Drug: Placebo throat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo throat spray
Study: 20961349
Drug: Combination Q-switched
Normalized name: Chew Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Q-switched Nd:YAG laser with topical carbon lotion followed by long-pulse Nd:YAG
Study: 15705723
Drug: Speaking twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speaking twice as loud as comfortable
Study: 9141936
Drug: Preemptive ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive ketamine (0.5 mg/kg followed by infusion of 10 micrograms.kg‐1.min‐1 until abdominal closure)
Study: 3556308
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 gel administration
Study: 3556308
Drug: PGE2 gel
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 gel group
Study: 11478762
Drug: Micronutrient appetite
Normalized name: APPETITE SUPPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient appetite normaliser formulation (neogadine) administered for up to 30 days
Study: 23552390
Drug: Brief Mindfulness-Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief Mindfulness-Based Therapy (MBT), 6 sessions over 3 weeks
Study: 22490903
Drug: Clopidogrel 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 150 mg group
Study: 2663735
Drug: Cefixime 200
Normalized name: cefixime 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 200 mg twice daily (plus placebo once daily)
Study: 2663735
Drug: Amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid 500 mg/125 mg thrice daily
Study: 26052790
Drug: Daily sensorimotor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily sensorimotor enrichment administered by parents along with standard care
Study: 26052790
Drug: Sensorimotor enrichment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensorimotor enrichment therapy
Study: 23487599
Drug: Plasma 25-hydroxyvitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma 25-hydroxyvitamin D increase (1-ng/mL)
Study: 22039430
Drug: Single-dose (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose (4 mL 1% TFV gel)
Study: 22039430
Drug: Multiple-dose (QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose (QD or BID for 2 weeks)
Study: 22039430
Drug: Multiple-dose (MD)
Normalized name: miconazole nitrate Topical Solution [Nail MD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose (MD)
Study: 22039430
Drug: Single-dose (SD)
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose (SD)
Study: 12816740
Drug: cilomilast, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilomilast, 15 mg two times a day
Study: 24714778
Drug: Cediranib 45
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib 45 mg/day
Study: 17286868
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart 70/30 (BIAsp 70/30)
Study: 9761503
Drug: Oxalate-rich diet
Normalized name: oxalate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxalate-rich diet (1211 mg calcium/day)
Study: 9761503
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and oxalate-rich diet (3858 mg calcium/day)
Study: 23353641
Drug: UDCA (17‐23
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA (17‐23 mg/kg/day)
Study: 19213086
Drug: Enoxaparin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 0.5 mg/kg
Study: 19213086
Drug: Enoxaparin 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 0.75 mg/kg
Study: 15945304
Drug: Unsplinted implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsplinted implants
Study: 11677200
Drug: Subcutaneous etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous etanercept 25 mg twice weekly
Study: 23340794
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of sodium restriction on habitual diet (Group A)
Study: 12655261
Drug: Celecoxib 100
Normalized name: celecoxib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 100 mg twice daily
Study: 2029860
Drug: Tramadol 75
Normalized name: traMADol 75 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 75 mg
Study: 8951985
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (0 mg) during abstinence
Study: 8951985
Drug: Nicotine patches
Normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patches (10 mg, 20 mg, 30 mg)
Study: 8951985
Drug: Nicotine abstinence
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine abstinence (0 mg patch)
Study: 1673577
Drug: Bopindolol (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bopindolol (a beta-blocker with a slightly expressed ISA)
Study: 1673577
Drug: Metoprolol (cardioselective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (cardioselective beta-blocker)
Study: 27076599
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase administration (drip and ship)
Study: 24577626
Drug: Temsirolimus 15
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus 15 mg once weekly and PLD 40 mg/m(2) once every 4 weeks
Study: 17937357
Drug: BOOT Camp
Normalized name: Booty Goo
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BOOT Camp Survival Training for Navy Recruits‐A Prescription (BOOT STRAP)
Study: 19377380
Drug: Hyaluronan-based heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronan-based heparin bonded preconnected circuits (Vision HFOGBS, Gish, California, USA) with low-systemic heparin (125 IU/kg, ACT >250 s)
Study: 19377380
Drug: Hyaluronan-based heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronan-based heparin bonded preconnected circuits (Vision HFOGBS, Gish, California, USA) with full dose heparin
Study: 9653434
Drug: New therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: New therapies for prevention and treatment of MAS
Study: 2273080
Drug: Guanfacine 1
Normalized name: guanfacine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine 1 mg every night
Study: 2273080
Drug: Prazosin 1
Normalized name: prazosin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin 1 mg three times a day
Study: 6269789
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg ranitidine intravenously
Study: 6269789
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg cimetidine intravenously
Study: 17530471
Drug: Lovastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20 mg daily titrated every 3 months for 18 months)
Study: 6145832
Drug: Tamoxifen and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen and/or subsequent endocrine therapy
Study: 31211607
Drug: Hypnotherapy (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnotherapy (weekly session for 1 month, total of four sessions)
Study: 28969439
Drug: CCBT (computer-assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCBT (computer-assisted cognitive-behavioral therapy) using the 'Good Days Ahead' program
Study: 26481083
Drug: candesartan/hydrochlorothiazide 16/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: candesartan/hydrochlorothiazide 16/12.5 mg/d
Study: 30893638
Drug: Guanidinoacetic acid
Normalized name: Guanidinoacetic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanidinoacetic acid (GAA) 600 mg/kg diet/day
Study: 30893638
Drug: Guanidinoacetic acid
Normalized name: Guanidinoacetic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanidinoacetic acid (GAA) 1200 mg/kg diet/day
Study: 30893638
Drug: Guanidinoacetic acid
Normalized name: Guanidinoacetic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanidinoacetic acid (GAA) 1800 mg/kg diet/day
Study: 30893638
Drug: Guanidinoacetic acid
Normalized name: Guanidinoacetic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanidinoacetic acid (GAA) 0 mg/kg diet/day (Control)
Study: 24293455
Drug: Fingolimod 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod 1.25 mg daily
Study: 24293455
Drug: Fingolimod 5
Normalized name: fingolimod 500 MCG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod 5 mg daily
Study: 17464718
Drug: Mifepristone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (600 mg day(-1)) for 7 days
Study: 15163892
Drug: Cessation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation of both therapies
Study: 11683695
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg simplified lansoprazole suspension (nasogastrically)
Study: 11683695
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg intravenous pantoprazole
Study: 9712471
Drug: 25‐mg ephedrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25‐mg ephedrine capsule
Study: 3167527
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral and systemic antibiotics (Group C)
Study: 31788791
Drug: Fast propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fast propofol infusion
Study: 31788791
Drug: Slow propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Slow propofol infusion
Study: 20043136
Drug: DBDS-MPH (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBDS-MPH (40 mg)
Study: 2141512
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (vincristine during irradiation and maintenance CCNU and vincristine, given in 6-weekly cycles for 1 year)
Study: 16097225
Drug: Chin cup
Normalized name: CHIN-UP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chin cup therapy with 600 g of force applied in 13 patients
Study: 9882760
Drug: Melatonin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (5 mg p.o.)
Study: 10445787
Drug: Increase of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase of MET dose from 375 mg (in groups B and C) to 750 mg/day (in group A)
Study: 25470746
Drug: Doravirine (6-1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doravirine (6-1,200 mg)
Study: 25470746
Drug: Doravirine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doravirine (120 mg) coadministered with midazolam
Study: 25470746
Drug: Doravirine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doravirine (up to 1,200 mg single doses and up to 750 mg multiple doses)
Study: 15909262
Drug: Azithromycin at
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin at 60 mg/kg per course
Study: 15909262
Drug: Azithromycin at
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin at 30 mg/kg per course
Study: 15909262
Drug: Three-day regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-day regimens of azithromycin (500 mg/day) in adults
Study: 15909262
Drug: 10-day comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day comparator antibiotics
Study: 24729507
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg twice daily for 7 days
Study: 2676266
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment with chlorthalidone and atenolol (or reserpine)
Study: 31185327
Drug: Post-mastectomy intensity
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-mastectomy intensity modulated proton therapy (IMPT)
Study: 23322466
Drug: Tocilizumab-MTX 4
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tocilizumab-MTX 4 mg/kg
Study: 19364000
Drug: morphine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 0.1 mg
Study: 19364000
Drug: morphine 0.2
Normalized name: morphine 0.23 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 0.2 mg
Study: 3064599
Drug: Furosemide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (50 mg)
Study: 31229329
Drug: Hydrogen peroxide
Normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrogen peroxide skin preparation
Study: 28930903
Drug: Localized cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Localized cold therapy
Study: 25578927
Drug: 22 g
Normalized name: Empty Carpuject 2 mL 22 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22 g freeze‐dried blueberry powder
Study: 22775199
Drug: Insulin euglycaemic
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin euglycaemic clamp
Study: 3071588
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg three times a day)
Study: 24705975
Drug: Pazopanib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib (600 mg)
Study: 24159785
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus thermoheliox (group 1)
Study: 18787899
Drug: Tiotropium (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (18 microg once daily for 7 days)
Study: 16169256
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) 1000 mg/day to 3000 mg/day as adjunctive therapy
Study: 15124554
Drug: Partial breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial breast irradiation (intraoperative radiotherapy, brachytherapy, or external radiotherapy using 3D conformal radiation therapy)
Study: 24231837
Drug: Oxybutynin vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin vaginal ring 4 mg daily
Study: 10702886
Drug: Cilostazol 100
Normalized name: cilostazol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol 100 mg
Study: 19958962
Drug: Intravenous allogeneic
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous allogeneic human mesenchymal stem cells (hMSCs)
Study: 31917835
Drug: Somapacitan 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somapacitan 0.04 mg/kg/wk
Study: 31917835
Drug: Daily GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily GH 0.034 mg/kg/d
Study: 31917835
Drug: Somapacitan 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somapacitan 0.08 mg/kg/wk
Study: 22306585
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose plus booster on day 21
Study: 12195350
Drug: Adjunctive therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive therapeutic vaccine trial (for 11 of the 16 subjects)
Study: 12195350
Drug: Discontinued therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinued therapy
Study: 24153411
Drug: 2-week taper
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week taper